– USA, CA – La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced the appointment of Larry Edwards as President and CEO.
“Larry has an impressive track record bringing innovative treatments that address unmet medical needs to patients in the acute-care setting,” said Board Chairman, Kevin Tang. “We are delighted to have Larry join the Company.”
About Larry Edwards
From 2015 to 2020, Mr. Edwards served in various positions at Tetraphase Pharmaceuticals, Inc., most recently serving as Chief Executive Officer. From 2014 to 2015, he served as Senior Director of Marketing of the Gram-negative Franchise of Cubist Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.). From 1999 to 2014, Mr. Edwards served in various positions at Merck and Co., Inc., most recently serving as Global Marketing Director of Clostridium Difficile and New Infectious Disease Products.
“I look forward to working with the La Jolla team to continue to expand patient access to GIAPREZA and XERAVA,” said Larry Edwards, President and CEO. “I am grateful to have the opportunity to join a company that focuses on improving outcomes in patients suffering from life-threatening diseases.”
Mr. Edwards received a B.S. degree in business and healthcare administration from Ohio University.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or another distributive shock. XERAVA, is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections.
For more information: https://www.lajollapharmaceutical.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
